Skip to content
by Legal Desire
19 August 2020

Latham Advises Momenta on US$6.5 Billion Acquisition by Johnson & Johnson

Advising firms

Deal team

18 lawyers named
LawyerFirmSeniorityPracticeOffice
Scott Shean Lead Latham & Watkins LLP Partner corporate Not stated
Peter Handrinos Lead Latham & Watkins LLP Partner corporate Not stated
Darren Guttenberg Latham & Watkins LLP Associate corporate Not stated
Christopher Lee Latham & Watkins LLP Associate corporate Not stated
Shannon Cheng Latham & Watkins LLP Associate corporate Not stated
Christopher Martinez Latham & Watkins LLP Associate corporate Not stated
Michael Egge Latham & Watkins LLP Partner antitrust Not stated
Patrick English Latham & Watkins LLP Counsel antitrust Not stated
Barrett Tenbarge Latham & Watkins LLP Associate antitrust Not stated
Matthew Conway Latham & Watkins LLP Partner benefits and compensation Not stated
Nikhil Kumar Latham & Watkins LLP Associate benefits and compensation Not stated
Lisa Watts Latham & Watkins LLP Partner tax Not stated
Shruti Hazra Latham & Watkins LLP Associate tax Not stated
Alan Tamarelli Latham & Watkins LLP Partner intellectual property Not stated
Elizabeth Richards Latham & Watkins LLP Partner regulatory Not stated
Betty Pang Latham & Watkins LLP Counsel regulatory Not stated
Nathan Beaton Latham & Watkins LLP Associate regulatory Not stated
Jenna Cooper Latham & Watkins LLP Partner general corporate Not stated

Stated terms

Stated value
USD 6.50bn (US$6.5 billion)
What the figure measures
Enterprise value
Client
Momenta Pharmaceuticals, Inc.Sell-side
Counterparties
Johnson & Johnson (Buy-side)